Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22039419 | 0.79 | CHRNB4 (0.46) | CHRNB4CHRNA3POLBHDAC8NISCH | |
| SCHEMBL1429750 | 0.79 | CHRNB4 (0.49) | CHRNB4CHRNA3POLBHDAC8NISCH | |
| SCHEMBL29420191 | 0.79 | CHRNB4 (0.49) | CHRNB4CHRNA3POLBHDAC8NISCH | |
| SCHEMBL22300218 | 0.76 | CHRNB4 (0.50) | CHRNB4CHRNA3HDAC8ALDH1A1CYP1A2 | |
| SCHEMBL22039523 | 0.76 | CHRNB4 (0.43) | CHRNB4CHRNA3 | |
| Methyl Alcohol SCHEMBL28796119 | 0.75 | CHRNB4 (0.45) | CHRNB4CHRNA3POLBNISCHALDH1A1 | |
| SCHEMBL2323955 | 0.74 | CHRNB4 (0.47) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL17353143 | 0.74 | CHRNB4 (0.56) | CHRNB4CHRNA3POLBHDAC8ALDH1A1 | |
| SCHEMBL31444456 | 0.73 | CHRNB4 (0.51) | CHRNB4CHRNA3POLBNISCHKMT2A | |
| SCHEMBL38652147 | 0.72 | CHRNB4 (0.46) | CHRNB4CHRNA3HDAC8ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | claimed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | claimed |
| CN-109608464-B | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | claimed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | claimed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | claimed |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | disclosed |
| CN-109608464-B | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | disclosed |
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
| EP-2155734-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144223-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885POLB 698/4885 |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885POLB 698/4885 |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | CHRNB4 4859/4885CHRNA3 4854/4885POLB 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.